key: cord-0984445-9nzdgtqc authors: Linschoten, M.; Asselbergs, F. W.; CAPACITY-COVID collaborative consortium,; Group, LEOSS Study title: Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across sixteen countries date: 2021-03-12 journal: nan DOI: 10.1101/2021.03.11.21253106 sha: 1d835bc458d25e39076990d1450f05b05558be14 doc_id: 984445 cord_uid: 9nzdgtqc Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. Method and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable modified Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 10,481 patients with COVID-19 were included (22.4% aged 66-75 years; 38.7% female) of which 30.5% had a history of cardiac disease. Patients with heart disease were older, predominantly male and more likely to have other comorbid conditions when compared to those without. COVID-19 symptoms at presentation did not differ between these groups. Mortality was higher in patients with cardiac disease (30.3%; n=968 versus 15.7%; n=1143). However, following multivariable adjustment this difference was not significant (adjusted risk ratio (aRR) 1.06 [95% CI 0.98-1.15, p-value 0.13]). Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for NYHA III/IV heart failure (aRR 1.43 [95% CI 1.22-1.68, p-value <0.001]) and atrial fibrillation (aRR 1.14 [95% CI 1.04-1.24, p-value 0.01]). None of the other heart disease subtypes, including ischemic heart disease, remained significant after multivariable adjustment. Conclusion There is considerable heterogeneity in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with severe heart failure are at greatest risk of death when hospitalized with COVID-19. Continuous variables in CAPACITY-COVID were categorized to align with LEOSS prior to merging the datasets 18 from these two different sources. Multiple imputation (R package mice) was performed to deal with missingness 19 across baseline variables required for the regression models through the generation of 10 imputed datasets. The 20 following variables were included in the multiple imputation model: all variables indicated with an asterisk in 21 Table 1 -3, and furthermore presence of pre-existing cardiac disease, arrhythmia/conduction disorder, heart 22 failure, coronary artery disease (CAD), valvular heart disease, extent of inclusion (all/random sample vs. selected For the main analyses, multivariable modified Poisson models with robust standard errors were used to 27 estimate the association between a history of cardiac disease and in-hospital mortality across the pooled ten 28 imputed datasets. Heterogeneity in associations was also determined across various clinically relevant subgroups 29 including age (≤65 and >65), sex, body mass index (BMI) (<30 and ≥30), diabetes, hypertension, chronic kidney 30 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint disease (CKD) and chronic obstructive pulmonary disease (COPD). In the secondary analyses, associations 1 between pre-defined specific types of heart disease and the in-hospital mortality were determined. The following 2 heart disease subtypes were analyzed: arrhythmias/conduction disorders, CAD, myocardial infarction (MI), heart 3 failure and valvular heart disease. To be able to determine differences in the association between the pre-defined 4 cardiac disease subtypes and in-hospital mortality in adults versus the elderly, analyses were also performed in 5 patients ≤65 years and >65 years. The cut-off was set at 65 since most COVID-19 vaccination strategies in Europe 6 have defined the elderly as those >65 years of age. 22 stratification by cohort of inclusion (CAPACITY-COVID vs. LEOSS; Table S4 ). Of symptoms overlapping with 23 CVD, chest pain was most common, reported by 8.3% of patients. Less than five percent of patients experienced 24 (pre) syncope, palpitations, orthopnea or peripheral edema (Table S4) . After stratification by age, the pattern of 25 complaints did not differ between patients with and without a history of cardiac disease ( Figure S3 ). Outcomes 28 The median duration of hospital admission was 9 [5 -19] days (Table 3) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint of patients admitted to a critical care unit increased with age until 75 years. Patients aged >75 years were 1 predominantly treated on the ward (Table S5) . Overall, the comorbidity burden among patients on a critical care 2 unit was lower than for patients admitted to the ward only ( Table S5 ). Patients that were admitted to a critical 3 care unit tended to be more ill at admission based on vitals and laboratory values at hospital admission ( Table 4 S6). During their hospital admission 20.1% (n=2111) of patients died. Mortality was strongly related to age, with 5 a mortality of 2% (n=3) in patients aged 18-25 years and 41.6% (n=363) in patients aged >85 years (Table S7) . Oxygen saturation levels were lower at admission in those who died, while the levels of inflammatory markers 7 (C-reactive protein and total white blood cell count) were higher (Table S8 ). In patients with cardiac disease 8 30.3% (n=968) died during their hospital admission versus 15.7% (n=1143) in patients without chronic heart 9 disease ( Table 3 ). In addition to heart disease, other comorbidities were also more prevalent in patients that died 10 during their hospital admission (Table S7) . Cardiac and thromboembolic complications 13 During hospitalization, serious cardiac complications including myocarditis, MI and new onset heart failure were 14 diagnosed in 0.3% (n=28), 0.6% (n=60) and 1.2% (n=115) of patients respectively (Table 3) . Other serious cardiac 15 complications registered only in CAPACITY-COVID, including malignant ventricular arrhythmias, endocarditis and pericarditis were also uncommonly diagnosed (<1% of patients; Table S9 ). MI and new onset heart failure was diagnosed more frequently in patients with pre-existing cardiac disease compared to those without (Table 3) . Among thromboembolic complications, pulmonary embolism was most prevalent being diagnosed in 4.2% (n=420) of patients ( Table 3) . All complications occurred more often in patients admitted to a critical care unit 20 and patients that died in-hospital (Table S10, S11), with the difference being most pronounced for pulmonary 21 embolism, which was diagnosed >10 times as often in the critically ill. Venous thromboembolic complications 22 were diagnosed less frequently among patients with a history of heart disease ( Table 3) . Association between prior history of cardiac disease and in-hospital mortality The multivariable modified Poisson regression model fitted in the total population yielded a non-statistically 26 significant association between any pre-existing cardiac disease and in-hospital mortality (aRR 1.06 [95% CI 0.98 27 1.15, p-value 0.13]) (Figure 1) . This association was further explored across different clinically relevant subgroups 28 (Table S12) . Apart from age (p-value interaction 0.03), the subgroup analyses did not reveal any significant 29 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint interactions with prior heart disease. Furthermore, sensitivity analyses by the exclusion of patients included from 1 centers that handled a selective inclusion (n=759) did not yield any different results (Table S13). Association between different pre-existing cardiac comorbidities and in-hospital mortality 4 To assess heterogeneity in the associations between different types of heart disease and hospital mortality, 5 modified Poisson regression models were fitted for all pre-specified cardiac disease subgroups. After 6 multivariable adjustment, the strongest association was found for NYHA III/IV heart failure and in-hospital 7 mortality (aRR 1.43 [95% CI 1.22 -1.68, p-value <0.001] (Figure 1) . Also, atrial fibrillation was found to be 8 significantly associated with in-hospital mortality (aRR 1.14 [95% CI 1.04 -1.24], p-value 0.01). For the other 9 heart disease subtypes, including ischaemic heart disease, no significant associations were found (Figure 1 , Table 10 S14). Since the elderly (>65 years) and adults with comorbidities are defined as two of the main risk groups being 12 prioritized in ongoing vaccination campaigns and statistical interaction was established between pre-existing 13 cardiac disease and age, associations between the various heart disease subtypes and in-hospital mortality were 14 also determined in patients ≤65 years and >65 years (Figure 2 A large proportion of patients developing severe COVID-19 have underlying CVD. The aim of this study was to 21 describe and compare the disease course and outcomes in hospitalized COVID-19 patients with and without preexisting cardiac disease. The most important findings of this work are (i) the symptoms of COVID-19 at 23 presentation are age dependent and do not differ in individuals with and without prior cardiac disease (ii) serious 24 incident cardiac complications are diagnosed infrequently during hospitalization and are seen more often in 25 patients with known cardiac disease at baseline (iii) the association between prior heart disease and in-hospital 26 mortality varies across heart disease subtypes where (iv) severe heart failure (NYHA III/IV) associates most 27 strongly with in-hospital mortality followed by (v) atrial fibrillation and (vi) there was no association with 28 ischemic heart disease. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint In line with others 23 , we found that COVID-19 symptoms at admission vary mainly with age with no 1 evidence that prior cardiac disease influences this relationship or the symptoms. Typical symptoms of COVID-2 19 including fever, cough and shortness of breath, were reported less often in the elderly. Overall complaints 3 mimicking cardiac disease, such as chest pain, palpitations and orthopnea were reported by only a minority of 4 patients (<10%). In this regard, it is interesting that cardiac-like symptoms such as chest pain and palpitations 5 have been reported by 17-44% and 20-32% of patients in the 2-3 months after the active infection as part of the 6 so-called "long COVID" syndrome. 24-27 Whether these complaints are related to cardiovascular involvement in 7 the convalescent phase of the disease or should predominantly be viewed as an epiphenomenon remains unclear. According to our study, serious cardiac complications are rarely diagnosed during hospitalization with 9 COVID-19, with a prevalence <2% of patients. To aid interpretation of these numbers it is of interest to relate them to the occurrence of cardiac complications in patients hospitalized for other (viral) infectious diseases. A 11 recent large French retrospective cohort study found that the prevalence of MI and atrial fibrillation was lower in 12 patients with COVID-19 than seasonal influenza with a prevalence of 0.6% vs. 1.1% and 12.4% vs. 15.8% 13 respectively. 7 Unfortunately, this study did not report the prevalence of any other cardiac complications, including 14 heart failure and myocarditis. As cardiomyocytes express ACE2 28,29 , the docking receptor of SARS-CoV-2, it has 15 been speculated that SARS-CoV-2 may infect cardiomyocytes, replicate in cardiac tissue and thereby induce 16 direct myocardial damage. These concerns have also been triggered by the finding that raised levels of troponin above test-specific upper limits are found in up to one third of patients at hospital admission. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. patients may have troponin elevations secondary to profound hypoxia and a supply/demand imbalance rather than 1 direct damage due to viral invasion in cardiac tissue. 31 However, the discrepancy in the limited number of patients 2 diagnosed with cardiac complications during hospitalization and the significant proportion of patients with 3 abnormal findings in imaging studies is a concern and warrants further investigation. Cardiac complications may 4 have been missed, due to the overlapping symptomatology with COVID-19 as well as limited access or performed 5 diagnostic tests. Contrary to cardiac complications, which in our study were rarely diagnosed during hospitalization, 7 venous thrombosis and thromboembolism are common features of COVID-19, with a prevalence 3-4 times higher 8 when compared to seasonal influenza. 7 Thromboembolic events are especially common in patients admitted to 9 the ICU, with pulmonary embolism being diagnosed more than 10 times as often (12.6% vs. 1.2%) in our cohort 10 compared to patients treated on the ward only. The prevalence of pulmonary embolism in the ICU population in 11 our study is lower than in studies based on data originating from patients hospitalized in the first months of the pandemic, that reported a prevalence of up to 20.6%. 36,37 This discrepancy most likely reflects the implementation 13 of enhanced antithrombotic prophylactic strategies in patients admitted with COVID-19 during the course of 2020. 14 Interestingly, we observed that thromboembolic complications were less common among patients known with 15 cardiac disease in our cohort. This observation is possibly related to pre-admission use of anticoagulants for the 16 treatment of pre-existing cardiac conditions. This will be explored in ongoing analyses. Among different heart disease subtypes, severe heart failure (NYHA class III/IV) was most strongly 18 associated with in-hospital mortality in this study across the spectrum of different heart disease subtypes. Others have also identified patients with heart failure as one of the groups at particular risk. 38 of being hospitalized in the presence of heart failure is also increased was recently investigated in a population-25 based study, which found an aOR of 4.43 (95% CI 2.59 -8.04; p-value <0.001). 40 Besides age and male sex, heart 26 failure had the strongest association with in-hospital mortality among various different comorbidities in this study. Apart from advanced heart failure, we also observed an independent association between pre-existing is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint incremental effect of new-onset atrial fibrillation with a history of atrial fibrillation on in-hospital mortality and 1 found an aRR of 1.18 [95% CI 1.04 -1.33]. 41 Whether pre-existing atrial fibrillation should be viewed as an 2 independent risk factor of in-hospital mortality or is primarily a proxy for underlying frailty in the elderly remains 3 to be explored. were associated with in-hospital mortality after adjustment for age, sex, BMI, diabetes, hypertension, CKD and 6 COPD. This heterogeneity was also evident in the population based study by Petrilli et al. in which patients with 7 CAD did not seem to be at increased risk of hospitalization due to COVID-19 (aOR was 1.08; 95% CI 0.81 -8 1.44; p-value 0.60). 40 It could therefore be questioned whether all patients with heart disease should be defined as 9 a group at risk, certainly when viewed in context of other demographic factors such as age and sex, as these appear 10 to contribute to COVID-19 outcome to a much larger extent than pre-existing cardiac disease. 12 As heart failure and atrial fibrillation are primarily diseases of the elderly, with a steep increase in the 12 prevalence as well as severity beyond the age of 75 years 42-44 , it is likely that a majority of patients with the heart 13 disease subtypes associated with the highest risk as identified in this study will be among the first to be vaccinated 14 according to current vaccine rollout strategies across Europe. 22 Adults with comorbidities are identified as an 15 additional priority group but current advice lacks detail on which comorbidities should be considered high-risk. Therefore, we also determined the strength per heart disease subtype and in-hospital mortality in patients <65 17 years. Due to the lower comorbidity burden in this group, we hypothesized that the associations for the different 18 types of heart disease would be higher in this patient population. For myocardial infarction and NYHA III/IV we 19 found a significant interaction with age, with an aRR that was higher in patients ≤65 years. However, we lacked 20 sufficient power to draw any strong conclusions from this finding. Limitations 23 Our study determines associations on a population level (e.g., all patients with heart failure) rather than individual 24 risks and is limited to patients with COVID-19 that were hospitalized. In some countries that provided data, 25 hospitalization and potentially life-sustaining treatments such as mechanical ventilation, might have been withheld 26 in those with high frailty, including those with severe heart failure, which may have led to an overestimation of 27 the found associations. Furthermore, we could not reliably investigate associations between heart disease subtypes 28 and HDU/ICU admission since we observed that patients admitted to a critical care unit were overall younger 29 with fewer comorbidities. Since age in particular is well-known to be associated with a more severe COVID-19 30 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint disease course, this difference in baseline characteristics in those admitted to HDU/ICU is suggestive of an 1 underlying selection of patients admitted for critical care. The mechanisms behind this selection are likely 2 complex, influenced by amongst others the variability in critical care bed numbers across participating countries 3 and available staff that may have led to demand for life-saving resources (nearly) exceeding supply, patient 4 preference as well as cultural differences in clinical decision making. A further study limitation is that we only 5 examined the impact of pre-existing CVD on in-hospital mortality, which excludes the many deaths that have 6 occurred in community settings and nursing homes. Finally, there was no central adjudication of events in either 7 of the two registries. Moreover, echocardiographic data, providing more in-depth insight into heart failure etiology 8 as well as the degree of systolic and diastolic dysfunction prior to hospitalization are lacking. The discrepancy between the low prevalence of clinically diagnosed cardiac complications among the most ill 16 requiring hospitalization and the large proportion of only mildly or even asymptomatic patients with abnormal 17 findings on CMR after the acute phase of the disease has ceased warrant further investigation to understand their 18 specificity and significance. In addition, studies on the long-term incidence of major adverse cardiac events 19 (MACE) are required. Future studies should also evaluate the added value of different pre-existing cardiac 20 comorbidities such as severe heart failure in prognostic models. Lastly, considering the high incidence of (venous) 21 thromboembolic events, the results of randomized controlled trials regarding the optimal antithrombotic 22 prophylactic strategy are much awaited. In this large retrospective cohort study across sixteen countries, more than one in three patients hospitalized with 26 COVID-19 had underlying chronic cardiac disease. Patients with a history of heart disease were older, more 27 frequently male and had a higher burden of other comorbid conditions at baseline. Inherently, patients with a 28 history of heart disease have a poorer outcome once infected with SARS-CoV-2. However, after multivariable 29 adjustment we did not find a significant association between chronic heart disease and in-hospital mortality. When is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint evaluating the associations between specific heart disease subtypes and in-hospital mortality, considerable 1 heterogeneity was detected. Of all patients with heart disease, those with severe heart failure are at greatest risk 2 of death when hospitalized with COVID-19. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint and innovation programme and EFPIA. Furthermore we want to thank the LEOSS study infrastructure group: is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint Tables 1 Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; 28. Department of Emergency Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; 64. Department of Cardiology, Elizabeth-TweeSteden Hospital, Tilburg, the Netherlands is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; 90. Department of Cardiology, Groene Hart Hospital, Gouda, the Netherlands is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.11.21253106 doi: medRxiv preprint Department of Cardiology, Hospital Group Twente, Almelo, the Netherlands 83. Division of Cardiology We want to express our gratitude and appreciation to all participating sites and researchers part of the CAPACITY- COVID collaborative consortium and LEOSS study and all research professionals that have contributed to the